Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria-CURE Results.
Kolkhir P, Laires PA, Salameh P, Asero R, Bizjak M, Košnik M, Dissemond J, van Doorn M, Hawro T, Kasperska-Zajac A, Zajac M, Kocatürk E, Peter J, Parisi CAS, Ritchie CA, Kulthanan K, Tuchinda P, Fomina D, Kovalkova E, Khoshkhui M, Kouzegaran S, Papapostolou N, Du-Thanh A, Kamegashira A, Meshkova R, Vitchuk A, Bauer A, Grattan C, Staubach P, Bouillet L, Giménez-Arnau AM, Maurer M, Weller K. Kolkhir P, et al. J Allergy Clin Immunol Pract. 2023 Feb;11(2):610-620.e5. doi: 10.1016/j.jaip.2022.11.016. Epub 2022 Dec 5. J Allergy Clin Immunol Pract. 2023. PMID: 36481420
Omalizumab Drug Survival in Chronic Urticaria: A Retrospective Multicentric French Study.
Litovsky J, Hacard F, Tétart F, Boccon-Gibod I, Soria A, Staumont-Sallé D, Doutre MS, Amsler E, Mansard C, Dezoteux F, Darrigade AS, Milpied B, Bernier C, Perrot JL, Raison-Peyron N, Paryl M, Droitcourt C, Demoly P, Grosjean J, Mura T, Du-Thanh A; Urticaria Study Group of French Dermatology Society. Litovsky J, et al. Among authors: du thanh a. J Allergy Clin Immunol Pract. 2023 Dec;11(12):3752-3762.e2. doi: 10.1016/j.jaip.2023.08.033. Epub 2023 Aug 29. J Allergy Clin Immunol Pract. 2023. PMID: 37652349 Free article.
Efficacy and Safety of Rituximab-Based Treatments in Angioedema With Acquired C1-Inhibitor Deficiency.
Kalmi G, Nguyen Y, Amarger S, Aubineau M, Bibes B, Blanchard-Delaunay C, Boccon-Gibod I, Bouillet L, Coppo P, Dalmas MC, Debord-Peguet S, Defendi F, Demoreuil C, Du-Thanh A, Gayet S, Hadjadj J, Jeandel PY, Launay D, Ly KH, Avoy CM, Niault M, Ollivier Y, Pelletier F, Porneuf M, Roos-Weil D, Fain O, Gobert D. Kalmi G, et al. Among authors: du thanh a. J Allergy Clin Immunol Pract. 2024 Jan;12(1):212-222. doi: 10.1016/j.jaip.2023.10.017. Epub 2023 Oct 14. J Allergy Clin Immunol Pract. 2024. PMID: 37844846
Non-Skin-Related Symptoms are Common in Chronic Spontaneous Urticaria and Linked to Active and Uncontrolled Disease: Results from CURE.
Pyatilova P, Hackler Y, Aulenbacher F, Asero R, Bauer A, Bizjak M, Day C, Dissemond J, Du-Thanh A, Fomina D, Giménez-Arnau AM, Grattan C, Gregoriou S, Hawro T, Kasperska-Zajac A, Khoshkhui M, Kocatürk E, Kovalkova E, Kulthanan K, Kuznetsova E, Makris M, Mukhina O, Pesqué D, Peter J, Salameh P, Siebenhaar F, Sikora A, Staubach P, Tuchinda P, Zamłyński M, Weller K, Maurer M, Kolkhir P. Pyatilova P, et al. Among authors: du thanh a. J Allergy Clin Immunol Pract. 2024 Apr 24:S2213-2198(24)00412-4. doi: 10.1016/j.jaip.2024.04.027. Online ahead of print. J Allergy Clin Immunol Pract. 2024. PMID: 38670260 Free article.
The Definition, Acronyms, Nomenclature, and Classification of Angioedema: AAAAI, ACAAI, ACARE, and APAACI DANCE Consensus.
Reshef A, Buttgereit T, Betschel SD, Caballero T, Farkas H, Grumach AS, Hide M, Jindal AK, Longhurst H, Peter J, Riedl MA, Zhi Y, Aberer W, Abuzakouk M, Al Farsi T, Al Sukaiti N, Al-Ahmad M, Altrichter S, Aygören-Pürsün E, Baeza ML, Bara NA, Bauer A, Bernstein JA, Boccon-Gibod I, Bonnekoh H, Bouillet L, Brzoza Z, Bygum A, Calderon O, de Albuquerque Campos R, Campos Romero FH, Cancian M, Chong-Neto HJ, Christoff G, Cimbollek S, Cohn DM, Craig T, Danilycheva I, Darlenski R, Du-Thanh A, Ensina LF, Fomina D, Fonacier L, Fukunaga A, Gelincik A, Giavina-Bianchi P, Godse K, Gompels M, Goncalo M, Gotua M, Guidos-Fogelbach G, Guilarte M, Kasperska-Zajac A, Katelaris CH, Kinaciyan T, Kolkhir P, Kulthanan K, Kurowski M, Latysheva E, Lauerma A, Launay D, Lleonhart R, Lumry W, Malbran A, Ali RM, Nasr I, Nieto-Martinez S, Parisi C, Pawankar R, Piñero-Saavedra M, Popov TA, Porebski G, Prieto Garcia A, Pyatilova P, Rudenko M, Sekerel BE, Serpa FS, Sheikh F, Siebenhaar F, Soria A, Staevska M, Staubach P, Stobiecki M, Thomsen SF, Triggiani M, Valerieva A, Valle S, Van Dinh N, Vera Ayala CE, Zalewska-Janowska A, Zanichelli A, Magerl M, Maurer M. Reshef A, et al. Among authors: du thanh a. J Allergy Clin Immunol. 2024 Apr 24:S0091-6749(24)00407-X. doi: 10.1016/j.jaci.2024.03.024. Online ahead of print. J Allergy Clin Immunol. 2024. PMID: 38670233
Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
Fabre M, Lamoureux A, Meunier L, Samaran Q, Lesage C, Girard C, Du Thanh A, Moulis L, Dereure O. Fabre M, et al. Among authors: du thanh a. Melanoma Res. 2024 Jun 1;34(3):241-247. doi: 10.1097/CMR.0000000000000963. Epub 2024 Mar 28. Melanoma Res. 2024. PMID: 38546723
122 results